Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oveporexton→

Oveporexton Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2460722-04-5
Molecular formula
C23H25F5N2O4S
Molecular weight
520.52 g/mol
Drug class
Selective orexin receptor 2 (OX2R) agonistwake-promoting agent
Mechanism of action
Directly activates orexin type 2 receptors (OX2R), restoring orexin signalling that is deficient in narcolepsy type 1. OX2R activation promotes wakefulness and supports regulation of sleep-wake states and cataplexy-related pathways.
Indications / reported uses
  • Treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults under the US ORZEYFUL product label (FDA approval August 5, 2026).

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220860Orig1s000lbl.pdf · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms · https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oveporexton Environmental Risk Assessment (ERA) (the Oveporexton ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.